DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for monoclonal gammopathy — screening already-approved drugs against its 16-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMonoclonal gammopathy maps to a 16-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for monoclonal gammopathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
CD38 molecule (CD38) — CD38 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet cxrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2O3S · 1.5 Å · ligand CYCLIC ADENOSINE DIPHOSPHATE-RIBOSE (CXR). Experimental structure, not a prediction.
What the evidence adds up to
In 19 patients with monoclonal gammopathy, plasma cell proliferative activity was evaluated using 5-bromo-2-deoxyuridine (BrdUrd) incorporation detected by an anti-BrdUrd monoclonal antibody, with simultaneous standard labelled thymidine incorporation as a reference test. The BrdUrd method was confirmed as a reliable test and recommended for routine clinical application in monoclonal gammopathies. No survival, response rates, or sample sizes beyond the 19 patients are given in that 1986 report.
A 2023 Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of monoclonal gammopathy of clinical significance (MGCS) and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed. No concrete numbers on survival or response rates are provided in that paper.
A 1985 report describes two cases of transient biclonal gammopathy, one with IgG kappa and IgA kappa monoclonal components and another with IgG1 kappa and IgG4 kappa monoclonal components. In both cases the second monoclonal component gradually disappeared. Anti-idiotypic antibodies were made against the major monoclonal serum component; in the first case the idiotype of the IgG kappa clone was not found in the IgA kappa plasma cells (real biclonal gammopathy), whereas in the second case the idiotypes of the two clones were identical (apparent biclonal gammopathy). The evolution to monoclonal gammopathy is discussed with regard to the existence of common malignant precursor cells in biclonal gammopathy. No survival or response rates are given.
What is still missing: prospective trials that link BrdUrd-based proliferative indices to clinical outcomes in MGUS or MGCS; a validated screening strategy with demonstrated mortality benefit; and patient stratification tools that distinguish transient from persistent biclonal gammopathies without reliance on custom anti-idiotypic antibodies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Tumori Journal · 1986 · 22 citations
Multiple Myeloma Plasma Cell Kinetics: Rapid and Reliable Evaluation using 5-Bromo-2-Deoxyuridine (BrdUrd) DNA Incorporation Detected by an Anti-BrdUrd Monoclonal Antibody
AbstractIn 19 patients with monoclonal gammopathy, plasma cell proliferative activity was evaluated using 5-bromo-2-deoxyuridine (BrdUrd) incorporation, as revealed by an anti-BrdUrd monoclonal antibody. A simultaneous standard labelled thymidine incorporation was carried out in all patients as reference test. The BrdUrd method was confirmed as a reliable test and is recommended for routine clinical application in monoclonal gammopathies.
British Journal of Haematology · 2023 · 14 citations · open access
Investigation and management of the monoclonal gammopathy of undetermined significance
AbstractThis Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed.
British Journal of Haematology · 1985 · 10 citations
Transient expression of a second monoclonal component in two forms of biclonal gammopathy
AbstractTwo cases of transient biclonal gammopathy are described, one having an IgG kappa and an IgA kappa monoclonal component and another with IgG1 kappa and IgG4 kappa monoclonal components. In both of these cases the second monoclonal component gradually disappeared. Anti-idiotypic antibodies were made against the major monoclonal serum component; in the first case the idiotype of the IgG kappa clone was not found in the IgA kappa plasma cells (real biclonal gammopathy) whereas in the second case the idiotypes of the two clones were identical (apparent biclonal gammopathy). The evolution to monoclonal gammopathy is discussed with regard to the existence of common malignant precursor cells in biclonal gammopathy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
